Durata Therapeutics Company Profile (NASDAQ:DRTX)

About Durata Therapeutics (NASDAQ:DRTX)

Durata Therapeutics logoDurata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:DRTX
  • CUSIP: 26658A10
  • Web: N/A
Average Prices:
  • 200 Day Moving Avg: $19.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.64
  • P/E Growth: 0
Dividend:
  • Dividend Yield: 1.0%
 

Frequently Asked Questions for Durata Therapeutics (NASDAQ:DRTX)

What is Durata Therapeutics' stock symbol?

Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."

Who are some of Durata Therapeutics' key competitors?

How do I buy Durata Therapeutics stock?

Shares of Durata Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Durata Therapeutics stock cost?

One share of Durata Therapeutics stock can currently be purchased for approximately $24.16.

Analyst Ratings

Consensus Ratings for Durata Therapeutics (NASDAQ:DRTX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Durata Therapeutics (NASDAQ:DRTX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Durata Therapeutics (NASDAQ:DRTX)
Earnings by Quarter for Durata Therapeutics (NASDAQ:DRTX)
Earnings History by Quarter for Durata Therapeutics (NASDAQ:DRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2014Q2($0.73)($0.61)ViewN/AView Earnings Details
5/8/2014Q114($0.61)($0.65)ViewN/AView Earnings Details
3/14/2014Q413($0.76)($0.59)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.52)($0.75)ViewN/AView Earnings Details
5/9/20131Q13($0.66)($0.86)ViewN/AView Earnings Details
11/9/2012Q312($1.00)($1.47)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Durata Therapeutics (NASDAQ:DRTX)
Current Year EPS Consensus Estimate: $-2.97 EPS
Next Year EPS Consensus Estimate: $-1.37 EPS

Dividends

Dividend History for Durata Therapeutics (NASDAQ:DRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Durata Therapeutics (NASDAQ:DRTX)
Insider Trades by Quarter for Durata Therapeutics (NASDAQ:DRTX)
Insider Trades by Quarter for Durata Therapeutics (NASDAQ:DRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/12/2014John Patrick Shannon JrInsiderBuy3,000$13.72$41,160.00View SEC Filing  
6/12/2014Paul R EdickCEOBuy3,000$15.23$45,690.00View SEC Filing  
5/12/2014Schutter Richard DeDirectorBuy15,000$15.57$233,550.00View SEC Filing  
3/21/2014Aisling Capital Iii Lpmajor shareholderSell100,649$15.74$1,584,215.26View SEC Filing  
12/3/2013Lisa GilesDirectorBuy1,000$10.95$10,950.00View SEC Filing  
5/20/2013Paul R EdickCEOBuy3,000$7.09$21,270.00View SEC Filing  
8/14/2012Paul R EdickCEOBuy5,000$8.65$43,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Durata Therapeutics (NASDAQ:DRTX)
Latest Headlines for Durata Therapeutics (NASDAQ:DRTX)
Source:
DateHeadline
finance.yahoo.com logo5 Stocks Moving on Unusual Volume
finance.yahoo.com - April 7 at 9:30 AM
finance.yahoo.com logoActavis to Buy Durata for $675 Million for Antibiotic
finance.yahoo.com - April 7 at 9:30 AM
finance.yahoo.com logoActavis Rumored to be Close to Acquiring Allergan
finance.yahoo.com - April 7 at 9:30 AM
finance.yahoo.com logoEsperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4%
finance.yahoo.com - April 7 at 9:29 AM
finance.yahoo.com logoArQule (ARQL) Shows Strength: Stock Adds 6 % in Session
finance.yahoo.com - April 7 at 9:29 AM

Social

Chart

Durata Therapeutics (DRTX) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff